Cullinan Therapeutics, Inc.
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $0
- Net income
- -$219.9M
- Total assets
- $448.4M
- Market cap
- $830.3M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $241.6M
- Operating income
- -$241.6M
- Income tax
- $0
- Net income
- -$219.9M
Balance sheet
- Total assets
- $448.4M
- Current assets
- $386.8M
- Total liabilities
- $39.6M
- Current liabilities
- $37.7M
- Shareholders’ equity
- $408.7M
Cash flow
- Operating cash flow
- -$175.8M
- Investing cash flow
- $180.0M
- Financing cash flow
- $1.1M
- Net cash flow
- $5.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $830.3M
- Shares outstanding
- 62.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 8, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $219.9M in FY2022.
- Trading 19% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cullinan Therapeutics, Inc..
Write a review
News about Cullinan Therapeutics, Inc.
News & sentiment via Polygon.io
